

Value-Based Assessment of New Medical Technologies: Framework for the Application of Multiple Criteria Decision Health Technology Assessment

Pharmacoeconomics

34, 435-446

DOI: [10.1007/s40273-015-0370-z](https://doi.org/10.1007/s40273-015-0370-z)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Importance of hemodialysis-related outcomes: comparison of ratings by a self-help group, clinicians, and health technology assessment authors with those by a large reference group of patients. Patient Preference and Adherence, 2016, Volume 10, 2491-2500.	0.8	13
2	Costâ€ effectiveness thresholds: pros and cons. Bulletin of the World Health Organization, 2016, 94, 925-930.	1.5	518
3	Multi-Criteria Decision Analysis for Assessment and Appraisal of Orphan Drugs. Frontiers in Public Health, 2016, 4, 214.	1.3	35
4	Critique of the American Society of Clinical Oncology Value Assessment Framework for Cancer Treatments: Putting Methodologic Robustness First. Journal of Clinical Oncology, 2016, 34, 2935-2936.	0.8	14
5	How Well Can Analytic Hierarchy Process be Used to Elicit Individual Preferences? Insights from a Survey in Patients Suffering from Age-Related Macular Degeneration. Patient, 2016, 9, 481-492.	1.1	19
6	Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs. Orphanet Journal of Rare Diseases, 2017, 12, 10.	1.2	41
7	Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as an Evidence-based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs) in Emerging Markets. Value in Health Regional Issues, 2017, 13, 1-6.	0.5	20
8	Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature. Pharmacoeconomics, 2017, 35, 727-740.	1.7	116
9	Patient Involvement in Health Technology Assessment. , 2017, , .		42
10	Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework. Social Science and Medicine, 2017, 188, 137-156.	1.8	135
11	Resource Allocation and Priority Setting in Health Care: A Multiâ€criteria Decision Analysis Problem of Value?. Global Policy, 2017, 8, 76-83.	1.0	47
12	Health technology assessment process of a cardiovascular medical device in four different settings. Journal of Comparative Effectiveness Research, 2017, 6, 591-600.	0.6	0
13	Decision Making and Priority Setting: The Evolving Path Towards Universal Health Coverage. Applied Health Economics and Health Policy, 2017, 15, 697-706.	1.0	8
14	Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL). Orphanet Journal of Rare Diseases, 2017, 12, 50.	1.2	72
15	Modelling multicriteria value interactions with Reasoning Maps. European Journal of Operational Research, 2017, 258, 1054-1071.	3.5	27
16	Health Technology Assessment and Appraisal of Therapies for Rare Diseases. Advances in Experimental Medicine and Biology, 2017, 1031, 221-231.	0.8	13
17	A new argumentative based reasoning framework with rough set for decision making. , 2017, , .		3
18	Treatment Is Worth a Lot - But Just How Much. Biomedicine Hub, 2017, 2, 1-10.	0.4	1

#	ARTICLE	IF	CITATIONS
19	Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting. BMC Medical Informatics and Decision Making, 2017, 17, 149.	1.5	23
20	Does MCDA Trump CEA?. Applied Health Economics and Health Policy, 2018, 16, 147-151.	1.0	17
21	Thresholds for decision-making: informing the cost-effectiveness and affordability of rotavirus vaccines in Malaysia. Health Policy and Planning, 2018, 33, 204-214.	1.0	14
22	“Fair innings”™ in the face of ageing and demographic change. Health Economics, Policy and Law, 2018, 13, 209-217.	1.1	11
23	Access to orphan drugs “ comparison across Balkan countries. Health Policy, 2018, 122, 583-589.	1.4	20
24	Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries. European Journal of Health Economics, 2018, 19, 123-152.	1.4	198
25	Pharmaceutical pricing in Japan: market evidence for rheumatoid arthritis treatment. Expert Review of Pharmacoeconomics and Outcomes Research, 2018, 18, 339-348.	0.7	1
26	Multiple Criteria Decision Analysis in Health Technology Assessment for Drugs: Just Another Illusion?. Applied Health Economics and Health Policy, 2018, 16, 1-4.	1.0	6
27	Valuing health states: is the MACBETH approach useful for valuing EQ-5D-3L health states?. Health and Quality of Life Outcomes, 2018, 16, 235.	1.0	4
29	Evaluating the Benefits of New Drugs in Health Technology Assessment Using Multiple Criteria Decision Analysis: A Case Study on Metastatic Prostate Cancer With the Dental and Pharmaceuticals Benefits Agency (TLV) in Sweden. MDM Policy and Practice, 2018, 3, 238146831879621.	0.5	5
30	Determining the Value of Two Biologic Drugs for Chronic Inflammatory Skin Diseases: Results of a Multi-Criteria Decision Analysis. BioDrugs, 2018, 32, 281-291.	2.2	15
31	A multi-criteria decision approach for ranking unmet needs in healthcare. Health Policy, 2018, 122, 878-884.	1.4	10
32	A Multiple Criteria Decision Making System for Setting Priorities. IFMBE Proceedings, 2019, , 357-361.	0.2	3
33	Application of decision making and fuzzy sets theory to evaluate the healthcare and medical problems: A review of three decades of research with recent developments. Expert Systems With Applications, 2019, 137, 202-231.	4.4	129
34	Could or Should We Use MCDA in the French HTA Process?. Pharmacoeconomics, 2019, 37, 1417-1419.	1.7	5
35	Multi-criteria decision analysis for health technology assessment: addressing methodological challenges to improve the state of the art. European Journal of Health Economics, 2019, 20, 891-918.	1.4	45
36	Comparison of weighting methods used in multicriteria decision analysis frameworks in healthcare with focus on low- and middle-income countries. Journal of Comparative Effectiveness Research, 2019, 8, 195-204.	0.6	92
37	Assessment of External Price Referencing and Alternative Policies. , 2019, , 369-419.		0

#	ARTICLE	IF	CITATIONS
38	HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries. <i>Health Policy</i> , 2019, 123, 140-151.	1.4	43
39	Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework. <i>Social Science and Medicine</i> , 2020, 246, 112595.	1.8	23
40	Multi-criteria Decision Analysis Software in Healthcare Priority Setting: A Systematic Review. <i>Pharmacoeconomics</i> , 2020, 38, 269-283.	1.7	18
41	Can multi-criteria decision analysis (MCDA) be implemented into real-world drug decision-making processes? A Canadian provincial experience. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 434-439.	0.2	6
42	ICER Value Framework 2020 Update: Recommendations on the Aggregation of Benefits and Contextual Considerations. <i>Value in Health</i> , 2020, 23, 1040-1048.	0.1	13
43	Potential Criteria for Frameworks to Support the Evaluation of Innovative Medicines in Upper Middle-Income Countriesâ€”A Systematic Literature Review on Value Frameworks and Multi-Criteria Decision Analyses. <i>Frontiers in Pharmacology</i> , 2020, 11, 1203.	1.6	7
44	Public Health Interventions with Harms and Benefits: A Graphical Framework for Evaluating Tradeoffs. <i>Medical Decision Making</i> , 2020, 40, 978-989.	1.2	1
45	The Importance of Collaboration in Pursuit of Patient-Centered Value Assessment. <i>Patient</i> , 2020, 14, 381-384.	1.1	5
46	Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis. <i>Medical Decision Making</i> , 2020, 40, 830-845.	1.2	8
47	Multicriterial analysis for the prioritization of technological alternatives for POCT blood gas equipment procurement in a high-complexity healthcare institution. <i>DYNA (Colombia)</i> , 2020, 87, 219-225.	0.2	0
48	Global Pharmaceutical Policy. , 2020, , .		7
49	Assessment and prioritization of the WHO â€œbest buysâ€”and other recommended interventions for the prevention and control of non-communicable diseases in Iran. <i>BMC Public Health</i> , 2020, 20, 333.	1.2	50
50	Advancing structured decisionâ€”making in drug regulation at the FDA and EMA. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 395-405.	1.1	18
51	Progressive Realisation of Universal Health Coverage in Low- and Middle-Income Countries: Beyond the "Best Buys". <i>International Journal of Health Policy and Management</i> , 2021, , .	0.5	5
52	Assessing social preferences in reimbursement negotiations for new Pharmaceuticals in Oncology: an experimental design to analyse willingness to pay and willingness to accept. <i>BMC Health Services Research</i> , 2021, 21, 234.	0.9	4
53	How to Value Orphan Drugs? A Review of European Value Assessment Frameworks. <i>Frontiers in Pharmacology</i> , 2021, 12, 631527.	1.6	24
54	Prioritizing Healthcare Interventions: A Comparison of Multicriteria Decision Analysis and Cost-Effectiveness Analysis. <i>Value in Health</i> , 2022, 25, 268-275.	0.1	3
55	Analytic Hierarchy Process. , 2017, , 135-147.		4

#	ARTICLE	IF	CITATIONS
56	Medicines Pricing: Limitations of Existing Policies and New Models. , 2020, , 99-137.		2
57	A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain. Global & Regional Health Technology Assessment, 0, 9, 14-21.	0.2	1
58	How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence. Health Policy, 2022, 126, 112-121.	1.4	2
59	Application of Multicriteria Decision Analysis to Determine the Value of Prophylaxis Relative to On-Demand Treatment in Hemophilia A and Emicizumab versus Replacement Therapy in the Greek Healthcare Setting. Clinical Drug Investigation, 2022, 42, 75-85.	1.1	2
61	Moving Beyond Quality-Adjusted Life-Years in Elderly Care: How Can Multicriteria Decision Analysis Complement Cost-Effectiveness Analysis in Local-Level Decision Making. Value in Health, 2022, 25, 1717-1725.	0.1	3
62	Multiple Criteria Decision Analysis (MCDA) for evaluating cancer treatments in hospital-based health technology assessment: The Paraconsistent Value Framework. PLoS ONE, 2022, 17, e0268584.	1.1	5
63	Multi-Criteria Decision Making in Healthcare. Advances in Computational Intelligence and Robotics Book Series, 2022, , 186-213.	0.4	1